Publications by authors named "P Bowness"

Article Synopsis
  • HLA-B*27 significantly increases the risk of developing spondyloarthritis (SpA), which encompasses various forms including axial SpA, peripheral arthritis, and inflammation in several areas of the body.
  • The exact mechanism by which HLA-B*27 contributes to SpA is unclear, but three major hypotheses suggest it may promote autoimmune responses, activate harmful immune pathways, and lead to misfolding issues that enhance inflammation and bone formation.
  • This review highlights current theories about HLA-B*27's role in SpA, notes recent advancements in research, identifies knowledge gaps, and suggests areas for future investigation.
View Article and Find Full Text PDF

HLA-B*27 was one of the first HLA alleles associated with an autoimmune disease, i.e., axial spondyloarthritis (axSpA) and acute anterior uveitis (B27AAU), which cause joint and eye inflammation, respectively.

View Article and Find Full Text PDF

Axial spondyloarthritis (axSpA) is characterized by type-17 immune-driven joint inflammation, and intestinal inflammation is present in around 70% of patients. In this study, we asked whether axSpA stool contained Th17-associated cytokines and whether this related to systemic Th17 activation. We measured stool cytokine and calprotectin levels by ELISA and found that patients with axSpA have increased stool IL-17A, IL-23, GM-CSF, and calprotectin.

View Article and Find Full Text PDF

Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a proinflammatory cytokine overproduced in several inflammatory and autoimmune diseases, including axial spondyloarthritis. Namilumab is a human IgG1 monoclonal anti-GM-CSF antibody that potently neutralises human GM-CSF. We aimed to assess the efficacy of namilumab in participants with moderate-to-severe active axial spondyloarthritis.

View Article and Find Full Text PDF